Occluder devices are estimated at 38.0% by product type in 2026 with atrial septal defect applications at 34.0% and hospitals at 43.0%. Adoption depends on anatomy-specific imaging and specialist catheterization capacity, yet narrow eligibility and long-term follow-up limit wider device use.